Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Determining complete remission in patients with AML

Christopher Hourigan • 4 Sep 2024
SOHO 2024
Acute Myeloid Leukemia Leukemia

Christopher Hourigan, DM, DPhil, FRCP, Virginia Tech FBRI Cancer Research Center, Washington, DC, discusses the complexity of determining complete remission (CR) in patients with acute myeloid leukemia (AML), emphasizing that no single test can confirm a cure. He explains the importance of integrating early indications of the most likely outcome with clinical information to guide treatment decisions. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Christopher Hourigan

Improving transplant outcomes in AML
Improving transplant outcomes in AML
Charles Craddock et al. • 12 Apr 2023
The importance of measurable residual FLT3-ITD before alloSCT for AML
1:33
The importance of measurable residual FLT3-ITD before alloSCT for AML
Christopher Hourigan • 4 Sep 2024
MRD as a surrogate endpoint for AML therapy
1:58
MRD as a surrogate endpoint for AML therapy
Christopher Hourigan • 4 Sep 2024
Updates in the diagnosis, classification & risk stratification of MDS
Updates in the diagnosis, classification & risk stratification of MDS
Christopher Hourigan et al. • 17 Jul 2024

Related Videos

Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
1:22
Continuous acalabrutinib versus acalabrutinib plus venetoclax in del(17p) or TP53-mutated CLL
Marta Coscia • 16 Oct 2026
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
1:35
Choosing between fixed-duration and continuous BTK inhibitor therapy in newly diagnosed CLL
Marta Coscia • 16 Oct 2026
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals